Fast track — ArticlesTherapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial
Introduction
Chaperonin 10, which is also called heat shock protein 10, is a 70 kDa mitochondrial protein (heptamer) known mainly for its role in intracellular protein folding, in concert with heat shock protein 60.1 Extracellular chaperonin 10 might have a role in the modulation of the innate immune response. The molecule has anti-inflammatory and immunomodulatory properties via inhibition of downstream events in Toll-like receptor (TLR) activated pathways.2 Due to their roles in the regulation and linking of the immune and inflammatory responses, TLRs and their exogenous and endogenous ligands, which propagate inflammation, are the subject of intense research.3, 4, 5 TLRs are highly expressed in synovial tissue3, 6, 7 and their activation contributes to the pathological processes of autoimmune and chronic inflammatory diseases such as rheumatoid arthritis. We have shown that chaperonin 10 inhibits both the TLR4-mediated induction of nuclear factor kappa B (NFκB) activation by lipopolysaccharide and the production of tumour necrosis factor (TNF) α and interleukin 6 in human peripheral blood mononuclear cells (PBMC) from healthy volunteers and patients with multiple sclerosis.2, 8
Although the initial trigger of rheumatoid arthritis is not defined, many cell populations seem to be implicated. Inflammatory cells—including monocytes, macrophages, dendritic cells, T cells, and B cells—infiltrate the synovial membrane, where together with chondrocytes, osteoclasts, and synovial fibroblasts they secrete cytokines, chemokines, and matrix metalloproteinases, inducing osteoclastogenic activity and resulting in the erosion of cartilage and bone.9, 10, 11, 12 Many pro-inflammatory cytokines (including TNFα, interleukin 1, and interleukin 6) and anti-inflammatory cytokines (interleukin 4, interleukin 10, tumour growth factor β) are released. The inflammatory response in rheumatoid arthritis is thought to be a result of the balance of these mediators shifting in favour of the pro-inflammatory cytokines, thus driving the arthritic process. TNFα is a critical mediator in the inflammatory response cascade9, 10, 11, 12 and is the target for several of the latest registered treatments for rheumatoid arthritis, including two monoclonal antibodies (infliximab and adalimumab)11, 13 and a recombinant TNF decoy receptor (etanercept).14, 15 The TNF inhibitors are more specific in their activity than are disease-modifying antirheumatic drugs (DMARDs; eg, methotrexate), which often become ineffective over time and can produce serious adverse events.16
The primary objective of this study was to determine the clinical efficacy and safety of chaperonin 10 in patients with moderate-to-severe active rheumatoid arthritis, even with concurrent treatment with standard DMARDs.
Section snippets
Participants
Otherwise healthy non-pregnant patients aged 18–75 years with disease duration of at least 6 months, onset of rheumatoid arthritis after 18 years of age (with one exception), and classified as American College of Rheumatology (ACR) functional class I–III17, 18 were eligible for enrolment. Enrolment criteria included active disease at screening, which was defined as eight or more tender and swollen joints, and either an ESR of 28 mm/h or more, a C-reactive protein (CRP) concentration of 10 mg/L
Results
Figure 1 shows the trial profile. The baseline characteristics of the three groups are shown in table 1. The ratio of women to men was higher in the 7·5 mg group than the other groups and three patients in the same group were not taking any concurrent DMARDs.
Three patients withdrew early from the study (figure 1). One patient in the 10 mg group reached the end of the study but failed to attend the safety follow-up visit. One patient in the 7·5 mg group withdrew because of an adverse event of
Discussion
Our findings suggest that treatment of individuals with active rheumatoid arthritis with chaperonin 10 results in short-term improvement of disease activity indicators, with improvements in symptoms seen as early as day 14 and sustained to day 84 of treatment. Rapid improvements in physical functioning and quality of life, as well as inhibition of cytokine production in vitro, were also seen.
This protocol was designed without placebo as an exploratory proof-of-principle investigation of the
References (26)
- et al.
Unfolding the role of chaperones and chaperonins in human disease
Trends Genet
(2001) - et al.
Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production
J Biol Chem
(2005) - et al.
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
Lancet
(2004) - et al.
Outstanding issues in use of disease-modifying agents in rheumatoid arthritis
Lancet
(1999) - et al.
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study
Clin Ther
(2003) - et al.
TLR signaling pathways
Semin Immunol
(2004) - et al.
Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?
Immunol Rev
(2004) - et al.
Limiting inflammatory responses during activation of innate immunity
Nat Immunol
(2005) - et al.
Negative regulation of toll-like receptor-mediated immune responses
Nat Rev Immunol
(2005) - et al.
Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma
Arthritis Rheum
(2004)
The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells
Arthritis Rheum
Phase 1a and 1b clinical trials of chaperonin 10 in healthy volunteers and patients with multiple sclerosis
J Neuro Sci
Joint inflammation and cytokine inhibition in rheumatoid arthritis
Clin Exp Med
Cited by (126)
Clinical trials and future perspectives of antiinflammatory agents
2023, Recent Developments in Anti-Inflammatory TherapyA tolerogenic dendritic cell–based therapy targeting heat shock protein–specific regulatory T cells in rheumatoid arthritis
2023, Translational Autoimmunity: Volume 6: Advances in Autoimmune Rheumatic DiseasesHeat shock protein is a key therapeutic target for nerve repair in autoimmune peripheral neuropathy and severe peripheral nerve injury
2021, Brain, Behavior, and ImmunityNanoparticle-siRNA: A potential strategy for rheumatoid arthritis therapy?
2020, Journal of Controlled ReleaseTherapeutic implications of toll-like receptors in peripheral neuropathic pain
2017, Pharmacological Research